4-((1-butyl-3-(4-(4-(1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)butanamido)phenyl)ureido)methyl)-N-hydroxybenzamide

ID: ALA5269955

Chembl Id: CHEMBL5269955

Max Phase: Preclinical

Molecular Formula: C42H48N10O9

Molecular Weight: 836.91

Associated Items:

Names and Identifiers

Canonical SMILES:  CCCCN(Cc1ccc(C(=O)NO)cc1)C(=O)Nc1ccc(NC(=O)CCCc2cn(CCOCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)nn2)cc1

Standard InChI:  InChI=1S/C42H48N10O9/c1-2-3-21-50(25-27-10-12-28(13-11-27)38(55)48-60)42(59)45-30-16-14-29(15-17-30)44-35(53)9-4-6-31-26-51(49-47-31)22-24-61-23-20-43-33-8-5-7-32-37(33)41(58)52(40(32)57)34-18-19-36(54)46-39(34)56/h5,7-8,10-17,26,34,43,60H,2-4,6,9,18-25H2,1H3,(H,44,53)(H,45,59)(H,48,55)(H,46,54,56)

Standard InChI Key:  ASTBYSZIHNGCIB-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA5269955

    ---

Associated Targets(Human)

HDAC6 Tclin Cereblon/Histone deacetylase 6 (114 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 836.91Molecular Weight (Monoisotopic): 836.3606AlogP: 3.72#Rotatable Bonds: 20
Polar Surface Area: 246.29Molecular Species: NEUTRALHBA: 13HBD: 6
#RO5 Violations: 3HBA (Lipinski): 19HBD (Lipinski): 6#RO5 Violations (Lipinski): 3
CX Acidic pKa: 9.05CX Basic pKa: 1.49CX LogP: 3.02CX LogD: 3.01
Aromatic Rings: 4Heavy Atoms: 61QED Weighted: 0.03Np Likeness Score: -1.34

References

1. Tomaselli D, Mautone N, Mai A, Rotili D..  (2020)  Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).,  207  [PMID:32871345] [10.1016/j.ejmech.2020.112750]
2. Wang C, Zhang Y, Wu Y, Xing D..  (2021)  Developments of CRBN-based PROTACs as potential therapeutic agents.,  225  [PMID:34411892] [10.1016/j.ejmech.2021.113749]
3. Li D, Yu D, Li Y, Yang R..  (2022)  A bibliometric analysis of PROTAC from 2001 to 2021.,  244  [PMID:36274273] [10.1016/j.ejmech.2022.114838]

Source